Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications; Results further characterize the safety and ef

Press/Media: Press / Media

PeriodJun 24 2018 → Jun 25 2018

Media coverage

4

Media coverage

  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications; Results further characterize the safety and ef
    Media name/outletPR Newswire
    CountryUnited States
    Date6/25/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications; Results further characterize the safety and ef
    Media name/outletPR Newswire
    CountryUnited States
    Date6/25/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications; Results further characterize the safety and ef
    Media name/outletPR Newswire
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications; Results further characterize the safety and ef
    Media name/outletPR Newswire
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo